Oppenheimer initiated coverage on Cleveland BioLabs (NASDAQ: CBLI ) with an Outperform rating and a $3 price target. Oppenheimer commented, "Biodefense drug development has a unique risk/reward risk profile. On the positive side, there is nondilutive capital from the government to cover R&D, no need for marketing/salesforce since government